Mercado global de tratamento da síndrome de Brown-Sequard – Tendências do setor e previsão para 2030

Análise e dimensão do mercado de tratamento da síndrome de Brown-Sequard

O aumento dos casos de lesões medulares e os avanços tecnológicos para o diagnóstico adequado também impulsionam o crescimento do mercado. Além disso, o aumento da parceria e colaboração entre os participantes do mercado e a crescente procura por terapias e medicamentos eficazes atuam como uma oportunidade para o crescimento do mercado. De acordo com a publicação do NCBI, a incidência global global de lesões traumáticas da medula espinal foi de 13,69 casos por 100.000 pessoas em 2023 e o número máximo de casos notificados em países de baixo e médio rendimento. Este número crescente de lesões traumáticas impôs a procura de terapias eficazes, pelo que se espera que proporcione ao mercado um crescimento rentável.                         

A Data Bridge Market Research analisa que o mercado global de tratamento da síndrome de brown-sequard, que foi de 35,73 mil milhões de dólares em 2022, subiria para 56,52 mil milhões de dólares até 2030 e deverá passar por um CAGR de 2, 55% durante o período de previsão de 2023 a 2030. Isto indica o valor de mercado. O “BSS traumático” domina o segmento de tipo do mercado global de tratamento da síndrome de Brown-Sequard devido ao aumento do número de pessoas que sofrem da síndrome de Brown-Sequard. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.    

Âmbito e segmentação do mercado de tratamento da síndrome de Brown-Sequard

Market Definition

Brown- Sequard syndrome is one of the neurological diseases which can be differentiated by the formation of lesions in spinal cord. The lesion formation results in paralysis (hemiparaplegia) or weakness on one side of the affected individual. Brown- Sequard syndrome can be caused by both the traumatic injuries and non- traumatic injuries. The most common traumatic injuries associated with BSS includes puncture wound to the back or neck among others. Inflammatory, infectious diseases, ischemia, tuberculosis, multiple sclerosis among others are few other diseases responsible for BSS. BSS caused by traumatic injuries can be diagnosed by X- ray or MRI, however in case of infectious etiologies purified protein derivative and sputum is frequently used so as to confirm the disease symptoms. Decompression surgery is most commonly preferred for BSS associated with trauma or tumor. In most of the BSS cases caused by infectious and other types of diseases, standard perioperative prophylactic antibiotics are recommended. Cervical collars and spinal orthosis are also used for treatment of BSS associated with neck or thoracolumbar region.

Global Brown-Sequard Syndrome Treatment Market Dynamics

Drivers

Rising cases of spinal cord injuries

As the awareness of spinal cord injuries and related conditions like Brown-Sequard Syndrome increases, more cases may be diagnosed and reported. This can lead to a higher demand for effective treatments and therapies, driving the growth of the market.

Advancements in Neurology and Neuroscience

The ongoing advancements in the field of neurology and neuroscience could contribute to the understanding of brown-sequard syndrome and potential treatment options. Emerging technologies, imaging techniques, and neuroscientific research may provide insights into the underlying causes and mechanisms of the disorder, driving innovation in the market.  

Opportunities

Development of Targeted Treatments

As understanding of the underlying mechanisms of brown-sequard syndrome  improves, there may be opportunities for the development of targeted treatments. Research and development efforts focused on identifying specific therapeutic approaches or interventions that can effectively manage the symptoms of brown-sequard syndrome  could present opportunities for pharmaceutical companies or medical device manufacturers.     

Restraints/Challenges

Low Prevalence and Awareness:

Brown-sequard syndrome is a rare condition, and its low prevalence makes it less of a priority for research, development, and investment compared to more common neurological disorders. The lack of awareness among healthcare professionals, patients, and the general public can lead to underdiagnosis and limited demand for specific treatments or interventions.

Limited Awareness and Recognition

Brown-sequard syndrome is a relatively rare and lesser-known condition, resulting in limited awareness among healthcare professionals, patients, and the general public. This lack of awareness can lead to underdiagnosis or misdiagnosis of the condition, delaying appropriate treatment and management.

Recent Developments

• In September 2021, Sumitomo Dainippon Pharma and Otsuka had announced a collaboration license agreement for four psychiatry and neurology compounds namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135. Under the terms of the partnership, Sunovion and Otsuka will split the costs and revenues of clinical trials, regulatory applications, and commercialization in each of these nations and areas. Additional ulotaront indications, and also SEP-378614 and SEP-380135 indications, will be identified after future Sumitomo Dainippon Pharma Group and Otsuka consultations

Global Brown-Sequard Syndrome Treatment Market Scope

The global brown-sequard syndrome treatment market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.  

Type

• Traumatic Bss
• Non- Traumatic Bss  

Treatment

• Devices
• Medication

 Route Of Administration

• Oral  
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Clinics
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Brown-Sequard Syndrome Treatment Market Regional Analysis/Insights

The global brown-sequard syndrome treatment market is analyzed and market size insights and trends are provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.  

The countries covered in the global brown-sequard syndrome treatment market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.

North America dominates the global brown-sequard syndrome treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, increasing cases of neurological conditions and rising number of research activities in this region. 

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in the government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global brown-sequard syndrome treatment market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global brown-sequard syndrome treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the transfection reagent and equipment market. The data is available for the historic period 2015-2020.    

Competitive Landscape and Global Brown-Sequard Syndrome Treatment Market  Share Analysis

O panorama competitivo do mercado global de tratamento da síndrome de Brown-Sequard fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, e domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.   

Alguns dos principais players que trabalham no mercado global de Tratamento da síndrome de Brown-Sequard são:   

• (EUA),
• B. Braun Medical Inc.(EUA),
• Sandoz Canada Inc. (Canadá),
• Aurobindo Pharma Limited (Índia),
• Fresenius Kabi Canadá (Canadá),
• Hikma (Reino Unido),
• AdvaCare Pharma (Índia),
• SteriMax (Índia),
• Baxter Healthcare (EUA),
• Stanex (EUA),
• Xellia Pharmaceuticals (Dinamarca),
• Concord Biotech (Índia),
• Abbott (EUA),
• Bayer AG (Alemanha),
• Tynoríndia (Índia),
• Integra LifeSciences Corporation (EUA),
• ERREGIERRE SpA (Itália),
• A Alquim Internacional Unip. Ltd.(Índia)

SKU-60167